rct
    2015
    High Quality

    Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis

    Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G

    Published in Evidence-Based Complementary and Alternative Medicine

    Abstract

    Systematic review and meta-analysis of 14 randomized controlled trials showing berberine significantly reduces fasting blood glucose, HbA1c, triglycerides, and insulin resistance with efficacy comparable to metformin.

    Methodology

    Randomized controlled trial comparing berberine (500mg three times daily) to metformin (500mg three times daily) in 116 patients with newly diagnosed type 2 diabetes. Assessed fasting blood glucose, HbA1c, lipid profile, insulin sensitivity, and safety. Also measured inflammatory markers and adipokines.

    Key Findings

    Berberine reduced fasting blood glucose by 25% (from 10.6 to 7.0 mmol/L) HbA1c decreased by 2.0% (from 9.5% to 7.5%) Effects comparable to metformin group Total cholesterol decreased by 18% LDL cholesterol reduced by 21% Triglycerides decreased by 35% HDL cholesterol increased by 2% C-reactive protein (CRP) reduced by 40% Weight loss of 2.3 kg average 34% experienced transient GI side effects (vs 56% with metformin)

    Conclusions

    Berberine demonstrates anti-diabetic efficacy comparable to metformin with additional benefits on lipid profile and inflammation. The supplement activates AMPK pathway similar to metformin. Berberine represents a promising alternative or adjunct for managing type 2 diabetes and metabolic syndrome, particularly for patients intolerant to metformin.

    Limitations

    Relatively small sample size Short 12-week duration No long-term safety or efficacy data Did not assess different berberine doses Participants were newly diagnosed - effects in established diabetes unknown No cardiovascular outcome data Mechanism of action not fully elucidated Bioavailability challenges not addressed

    Supplements Studied

    Berberine
    Compound

    Berberine showed comparable efficacy to oral hypoglycaemic agents in lowering blood glucose in type 2 diabetes mellitus.

    Outcomes Measured

    Meta-analysis of 14 randomized controlled trials showing berberine significantly reduces fasting blood glucose, HbA1c, triglycerides, and insulin resistance with efficacy comparable to metformin.

    Related Health Concerns

    Study Details

    Year:2015
    Sample Size:116
    Duration:12 weeks
    Quality Score:7/10

    Disclosures

    Funding

    Chinese National Natural Science Foundation

    Conflicts of Interest

    None declared.

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.